Home Cart Sign in  
Chemical Structure| 500287-72-9 Chemical Structure| 500287-72-9

Structure of Rilpivirine
CAS No.: 500287-72-9

Chemical Structure| 500287-72-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with anti-HIV effect.

Synonyms: R278474; TMC278; DB08864

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Sutar, Yogesh ; Adams, Joseph S ; Wu, Xiangmeng ; Bhoyarekar, Vaibhavi ; Garcia Diaz, Monica ; Wallace, Jennillee , et al.

Abstract: Rilpivirine (RPV) is a potent antiretroviral drug used for the long-term management of HIV infection. The high crystallinity and very low aqueous solubility of RPV are responsible for the highly variable pharmacokinetics of RPV seen in HIV-infected patients. While fatty meals can increase the absorption of RPV, the low lipid solubility of RPV precludes the development of oral lipid-based formulations such as self-nanoemulsifying systems (SNES). To improve the oral delivery of RPV, we evaluated the potential of six biocompatible bulky anions to transform RPV into amphiphilic RPV ionic liquids with high lipid solubility and only sodium docusate successfully yielded an amphiphilic RPV ionic liquid (IL), RPV docusate (RPV-Doc). Spectroscopic, chromatographic, and thermal characterization techniques confirmed the formation of RPV-Doc as an IL. RPV-Doc showed remarkably higher (∼100−200-fold) solubility in lipids compared to pure RPV. RPV-Doc was incorporated into two SNES formulations that, depending upon the composition of the SNES formulation, yielded a <100 or <250 nm nanoemulsion irrespective of the pH of the dilution medium. Oral pharmacokinetics and biodistribution studies in mice showed that both SNES formulations containing RPV-Doc yielded rapid and significantly higher oral bioavailability (∼6-fold higher Cmax and AUC) of RPV compared to the RPV suspension. Furthermore, compared to the RPV suspension, both SNES formulations containing RPV-Doc resulted in significantly higher and sustained RPV levels in the HIV sanctuary sites such as mesenteric lymph nodes and the brain. Taken together, our innovative approach can be used to improve the oral bioavailability and tissue penetration of RPV, which can eventually result in a reduction in the pharmacokinetic variability and therapeutic dose of RPV leading to optimal drug utilization.

Keywords: HIV reservoirs ; Transcutol ; Labrafac MC60 ; Capryol 90 ; nanoemulsion

Purchased from AmBeed:

Alternative Products

Product Details of Rilpivirine

CAS No. :500287-72-9
Formula : C22H18N6
M.W : 366.42
SMILES Code : N#CC1=CC=C(NC2=NC=CC(NC3=C(C)C=C(/C=C/C#N)C=C3C)=N2)C=C1
Synonyms :
R278474; TMC278; DB08864
MDL No. :MFCD11046372
InChI Key :YIBOMRUWOWDFLG-ONEGZZNKSA-N
Pubchem ID :6451164

Safety of Rilpivirine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Xenopus laevis oocytes 20 μM 1 hour To assess the accumulation of rilpivirine in oocytes expressing various transporters, results showed rilpivirine was not significantly transported by any of the tested transporters PMC3811300
Human monocyte-derived macrophages (MDM) 0.2–200 μM (based on RPV concentration) 12 hours Evaluate the effects of EuCF-RPV particles on MDM cell vitality. At the highest concentration tested, 200 μM, NRPV and EuCF-RPV less effected cell vitality than native RPV (82.9%, 56.9% and 37.9%, respectively). PMC6556898
Human preadipocytes 10 μM 15 days Rilpivirine at 10 μM significantly impaired adipocyte differentiation and induced the expression and release of proinflammatory cytokines. PMC3370806
Human preadipocytes 4 μM 15 days Rilpivirine at 4 μM significantly impaired adipocyte differentiation, but the effect was milder than that of efavirenz at the same concentration. PMC3370806
Human preadipocytes 0.01-10 μM 15 days Rilpivirine had no effect on the acquisition of adipocyte morphology at concentrations up to 2 μM, but significantly impaired adipocyte differentiation at 4 μM and 10 μM. PMC3370806
CEM-CD4+ T cells 0.1–1000 nM 2 hours Determine the EC50 of M3RPV and RPV in CEM-CD4+ T cells. Results showed that M3RPV had a 6.8-fold higher EC50 compared to RPV. PMC6875695
Human monocyte-derived macrophages (MDMs) 20 μM 24 hours To evaluate the uptake and antiviral efficacy of LBNP-RPV-CCR5 in MDMs. Results showed that LBNP-RPV-CCR5 had a 3-fold higher uptake at 12 h compared to LBNP-RPV and entered cells via CCR5 receptor-mediated pathways. PMC11711180
U-937 0.625-40 µM 24, 48, or 72 hours Evaluate the inhibitory effect of Rilpivirine on U-937 cell proliferation, showing GI50 values of 4.12-12.39 µM PMC9954146
K-562 0.625-40 µM 24, 48, or 72 hours Evaluate the inhibitory effect of Rilpivirine on K-562 cell proliferation, showing GI50 values of 4.12-12.39 µM PMC9954146
NB4 0.625-40 µM 24, 48, or 72 hours Evaluate the inhibitory effect of Rilpivirine on NB4 cell proliferation, showing GI50 values of 4.12-12.39 µM PMC9954146
HL-60 0.625-40 µM 24, 48, or 72 hours Evaluate the inhibitory effect of Rilpivirine on HL-60 cell proliferation, showing GI50 values of 4.12-12.39 µM PMC9954146
LX-2 cells 1-8 μM 24-48 hours To evaluate the effect of RPV on autophagy in TGF-β-activated LX-2 cells. Results showed that RPV enhanced the expression of autophagy markers, increased autophagosome content and lysosomal mass. PMC9021290
SLC22A1-overexpressing KCL22 cells 20 μM 30 minutes To assess the accumulation of rilpivirine in SLC22A1-overexpressing cells, results showed significantly higher accumulation in SLC22A1-overexpressing cells compared to control cells PMC3811300
CEMVBL100 cells 20 μM 30 minutes To assess the accumulation of rilpivirine in ABCB1-overexpressing cells, results showed no significant difference in accumulation between CEMVBL100 and CEM cells PMC3811300
Primary human hepatic stellate cells 1-8 μM 48 hours To verify whether RPV also enhances autophagy in non-immortalized primary HSC. Results showed that RPV similarly enhanced autophagy in primary HSC. PMC9021290
Caco-2 cell monolayers 20 μM 60 minutes To assess the permeability of rilpivirine in Caco-2 cell monolayers, results showed significantly higher transport in the B-to-A direction than A-to-B direction, but ABCB1 inhibitor tariquidar did not significantly alter permeability PMC3811300
CD4+ T cells 100 μM 8 hours Assessed uptake and cell vitality of RPV-NC in CD4+ T cells, showing no cytotoxicity and maximum uptake at 8 hours (8 μg/10^6 cells) PMC7334833
Human monocyte-derived macrophages (MDM) 100 μM 8 hours Assessed uptake and cell vitality of RPV-NC in macrophages, showing no cytotoxicity and maximum uptake at 6 hours (60 μg/10^6 cells) PMC7334833
Human monocyte-derived macrophages (MDM) 25 μM RPV 8 hours Assess uptake and retention of EuCF-RPV particles in MDM. At 8 hours, cells contained 14 μg/106 cells of RPV, 9.5 μg iron/106 cells and 2.9 μg cobalt/106 cells. PMC6556898

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice HL-60 xenograft model Oral 200 mg/kg Once daily for 15 days Evaluate the anti-leukaemic efficacy of Rilpivirine in the HL-60 xenograft model, showing significant inhibition of tumour growth PMC9954146
Humanized mice (hu mice) HIV-1-infected humanized mouse model Tail vein injection 25 mg/kg Single dose, lasting 14 days To evaluate the antiviral efficacy and biodistribution of LBNP-RPV-CCR5 in HIV-1-infected humanized mice. Results showed that LBNP-RPV-CCR5 specifically accumulated in the spleen and enhanced brain delivery via FUS-mediated BBB disruption. PMC11711180
Male Balb/cJ mice Healthy mice Intravenous injection 45 mg/kg Single injection, observed up to 28 days Evaluate tissue biodistribution and antiretroviral activities of 111InEuCF-PCL/RPV particles in mice. Particles accumulated in liver, spleen, and lymph nodes and were validated by MRI and SPECT/CT imaging. PMC6556898
C57BL/6J mice HFD-induced NAFLD model and CCl4-induced hepatotoxicity model Oral 5 mg/kg/day Once daily for 12 weeks (NAFLD model) or 4 weeks (CCl4 model) To evaluate the hepatoprotective effect of RPV in chronic liver injury models and its impact on autophagy. Results showed that RPV enhanced hepatic autophagy and attenuated liver injury. PMC9021290

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02491242 - Completed - Spain ... More >> Ramon y Cajal Hospital Madrid, Spain, 28034 Less <<
NCT02605954 HIV-1 Infection Phase 3 Completed - -
NCT03631732 HIV-1 Infection Phase 3 Recruiting August 2020 -
NCT02157311 HIV-1 Infection Phase 3 Completed - France ... More >> Hôpital Meynard Fort-de-france, Martinique, France, 97261 Hôpital Avicenne Bobigny, France, 93000 CHU Côte de Nacre Caen, France, 14033 Centre Hospitalier Sud Francilien Corbeil Essonnes, France, 91100 Hôpital Le Bocage Dijon, France, 21079 Hôpital Raymond Poincaré Garches, France, 92380 Hôpital Bicêtre Kremlin Bicetre, France, 94275 Hôpital Gui de Chauliac Montpellier, France, 34295 Hôpital Saint-Antoine Paris, France, 75012 Hôpital Pitié-Salpêtrière Paris, France, 75013 Hôpital Européen Georges Pompidou Paris, France, 75015 Hôpital Necker Paris, France, 75015 Hôpital Bichat Paris, France, 75018 Hôpital Tenon Paris, France, 75020 Hôpital Foch Suresnes, France, 92151 Hôpital Purpan Toulouse, France, 31059 Hôpital Bretonneau Tours, France, 37044 Less <<
NCT02858401 HIV-1 Infection Phase 1 Active, not recruiting June 2019 United States, California ... More >> Mills Clinical Research Los Angeles, California, United States, 90069 UCSD Antiviral Research Center (AVRC) San Diego, California, United States, 92103 United States, Florida Midway Immunology & Research Center Fort Pierce, Florida, United States, 34982 Orlando Immunology Center Recruiting Orlando, Florida, United States, 32803 United States, Ohio Ohio State University Infectious Diseases Research Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Central Texas Clinical Research Austin, Texas, United States, 78705 United States, Washington Peter Shalit, MD Seattle, Washington, United States, 98104 Less <<
NCT02605954 - Completed - -
NCT01814722 - Terminated(The trial was termi... More >>nated early due to slow recruitment.) Less << - -
NCT02440789 HIV-1 Infection Phase 1 Phase 2 Completed - -
NCT01495702 Acquired Immunodeficiency Synd... More >>rome HIV Infections Less << Phase 3 Completed - -
NCT00537966 HIV Infections Not Applicable Recruiting January 2025 Switzerland ... More >> University of Zurich Recruiting Zurich, Switzerland Contact: Huldrych. Günthard       Huldrych.guenthard@usz.ch Less <<
NCT00955968 HIV Infection Phase 4 Completed - -
NCT01500616 Hepatitis C, Chronic Phase 3 Completed - Belgium ... More >> Antwerpen, Belgium Brussel, Belgium Bruxelles, Belgium Charleroi, Belgium Gent, Belgium Leuven, Belgium Liège, Belgium Germany Berlin, Germany Bonn, Germany Dortmund, Germany Frankfurt, Germany Hannover, Germany Köln, Germany Stuttgart, Germany Tübingen, Germany Hungary Budapest, Hungary Ireland Dublin, Ireland Luxembourg Luxembourg, Luxembourg Portugal Amadora, Portugal Lisboa, Portugal Lisbon, Portugal Porto, Portugal Russian Federation Perm, Russian Federation Saint-Petersburg, Russian Federation St Petersburg, Russian Federation Toliatti, Russian Federation Volgograd, Russian Federation Yoshkar - Ola, Russian Federation United Kingdom Glasgow, United Kingdom Liverpool, United Kingdom London, United Kingdom Plymouth, United Kingdom Less <<
NCT01495702 - Completed - -
NCT03256422 HIV Infections Phase 3 Active, not recruiting December 2020 -
NCT01814722 - Terminated(The trial was termi... More >>nated early due to slow recruitment.) Less << - -
NCT02660905 Human Immunodeficiency Virus ... More >> Hepatitis C, Chronic Less << Phase 3 Active, not recruiting December 2017 Canada, Ontario ... More >> The Ottawa Hospital, General Campus Ottawa, Ontario, Canada Canada, Quebec The Research Institute of the McGill University Health Centre Montreal, Quebec, Canada, H4A 3J1 Less <<
NCT01908660 - Completed - Spain ... More >> Hospital Universitario de Valme Seville, Spain, 41014 Less <<
NCT02397096 HIV-1 Infection Phase 3 Active, not recruiting November 2, 2021 -
NCT00955968 - Completed - -
NCT03635788 HIV Infections Phase 3 Not yet recruiting June 22, 2024 United States, California ... More >> University of Southern California CRS Not yet recruiting Los Angeles, California, United States, 90033-1079 Contact: Luis M. Mendez    323-343-8283    lmendez@usc.edu    UCLA CARE Center CRS Not yet recruiting Los Angeles, California, United States, 90035 Contact: Arezou S. Akha, M.D., M.S.    310-557-3798    asadighi@mednet.ucla.edu    UCSD Antiviral Research Center CRS Not yet recruiting San Diego, California, United States, 92103 Contact: Jill Kunkel, R.N.    619-543-8080    jkunkel@ucsd.edu    Ucsf Hiv/Aids Crs Not yet recruiting San Francisco, California, United States, 94110 Contact: Jay Dwyer    415-476-4082 ext 353    Jay.Dwyer@ucsf.edu    Harbor-UCLA CRS Not yet recruiting Torrance, California, United States, 90502 Contact: Mario Guerrero    424-201-3000 ext 7318    mguerrero@labiomed.org    United States, Colorado University of Colorado Hospital CRS Not yet recruiting Aurora, Colorado, United States, 80045 Contact: Suzanne Fiorillo, M.S.P.H.    303-724-5931    suzanne.fiorillo@ucdenver.edu    United States, Georgia The Ponce de Leon Center CRS Not yet recruiting Atlanta, Georgia, United States, 30308-2012 Contact: Ericka Patrick, M.S.N.    404-616-6313    erpatri@emory.edu    United States, Massachusetts Massachusetts General Hospital CRS (MGH CRS) Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N.    617-724-0072    tflynn@partners.org    Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS Not yet recruiting Boston, Massachusetts, United States, 02115 Contact: Cheryl E. Keenan, R.N.    617-732-5635    CKeenan@BWH.Harvard.edu    United States, Missouri Washington University Therapeutics (WT) CRS Not yet recruiting Saint Louis, Missouri, United States, 63110-1010 Contact: Michael K. Klebert    314-747-1098    mklebert@dom.wustl.edu    United States, New York Weill Cornell Chelsea CRS Not yet recruiting New York, New York, United States, 10010 Contact: Todd Stroberg, R.N., B.S.N.    212-746-7198    tstrober@med.cornell.edu    Columbia P&S CRS Not yet recruiting New York, New York, United States, 10032-3732 Contact: Steven Palmer, P.A. -C    212-342-2958    sp500@cumc.columbia.edu    Weill Cornell Uptown CRS Not yet recruiting New York, New York, United States, 10065 Contact: Rebecca Fry, M.S.N., FNP    212-746-4166    ref2007@med.cornell.edu    United States, North Carolina Chapel Hill CRS Not yet recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Becky Straub, B.S.N., M.P.H.    919-843-9975    bstraub@med.unc.edu    Greensboro CRS Not yet recruiting Greensboro, North Carolina, United States, 27401 Contact: Kim Epperson, R.N., B.S.N., CRC    336-832-3262    kim.epperson@conehealth.com    United States, Ohio Cincinnati Clinical Research Site Not yet recruiting Cincinnati, Ohio, United States, 45219 Contact: Sharon Kohrs, R.N., B.S.N.    513-584-6383    kohrssd@ucmail.uc.edu    Case Clinical Research Site Not yet recruiting Cleveland, Ohio, United States, 44106 Contact: Jane Baum, R.N.    216-844-2546    jb@clevelandactu.org    United States, Pennsylvania Penn Therapeutics, CRS Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Eileen B. Donaghy, C.R.N.P.    215-349-8092    eileen.donaghy2@uphs.upenn.edu    United States, Rhode Island The Miriam Hospital Clinical Research Site (TMH CRS) CRS Not yet recruiting Providence, Rhode Island, United States, 02906 Contact: Pamela Poethke, R.N.    401-793-4971    ppoethke@lifespan.org    United States, Tennessee Vanderbilt Therapeutics (VT) CRS Not yet recruiting Nashville, Tennessee, United States, 37204 Contact: Beverly O. Woodward, M.S.N., R.N.    615-936-8516    beverly.o.woodward@vanderbilt.edu    United States, Washington University of Washington AIDS CRS Not yet recruiting Seattle, Washington, United States, 98104-9929 Contact: Christine Jonsson    206-744-8886    cjonsson@u.washington.edu    Puerto Rico Puerto Rico AIDS Clinical Trials Unit CRS Not yet recruiting San Juan, Puerto Rico, 00935 Contact: Sylvia I. Davila Nieves, M.Sc.    787-767-9192    sylvia.davila1@upr.edu    San Juan City Hosp. PR NICHD CRS Not yet recruiting San Juan, Puerto Rico, 00936 Contact: Lizbeth Fabregas-Troche, B.S., M.S.    787-764-3083    lfabregas@sanjuanciudadpatria.com Less <<
NCT02547844 HIV-1 Phase 4 Completed - Spain ... More >> Hospital Universitari Vall d'Hebron Barcelona, Spain, 08035 Less <<
NCT02447016 HIV Phase 4 Terminated(no more participant... More >>s taking atripla) Less << - Israel ... More >> Sheba Medical Center Ramat Gan, Israel, 52621 Less <<
NCT03194165 - Recruiting June 2019 France ... More >> Cochin Hospital Recruiting Paris, France, 75014 Contact: Jean-Marc TRELUYER, MD, PhD    +33 1 58 41 28 84    jean-marc.treluyer@aphp.fr    Principal Investigator: Jean-Marc TRELUYER, MD, PhD Less <<
NCT02470650 Patient Compliance ... More >> Antiretroviral Therapy Intolerance Less << Phase 4 Unknown October 2017 Spain ... More >> Josep Mallolas Masferrer Recruiting Barcelona, Spain, 08025 Contact: Joan Albert Arnaiz, MD    932275400 ext 3898    jaarnaiz@clinic.ub.es    Contact: ana Cruceta, MD       acruceta@clinic.ub.es Less <<
NCT02799264 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 1 Completed - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT02196064 - Completed - Spain ... More >> Fundación Pública Andaluza Progreso y Salud Sevilla, Spain, 41092 Less <<
NCT01701895 - Completed - United States, North Carolina ... More >> University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599-7215 Less <<
NCT02308332 Neurocognitive Decline ... More >> HIV Associated Neurocognitive Disorder Less << Phase 4 Completed - Netherlands ... More >> UMC Utrecht Utrecht, Netherlands Less <<
NCT01792570 Human Immunodeficiency Virus Phase 3 Unknown October 2017 Italy ... More >> Clinica delle Malattie Infettive, Policlinico Universitario Recruiting Bari, BA, Italy Contact: Gioacchino Angarano, M.D.       g.angarano@clininf.uniba.it    Principal Investigator: Gioacchino Angarano, M.D.          Divisione di Malattie Infettive, Ospedale S. Maria Annunziata, Antella Recruiting Firenze, FI, Italy Contact: Sergio Lo Caputo, M.D.       sergio.locaputo@asf.toscana.it    Principal Investigator: Sergio Lo Caputo, M.D.          Clinica delle Malattie Infettive, Ospedale San Martino, Università degli Studi Recruiting Genova, GE, Italy Contact: Antonio Di Biagio, M.D.       antonio.dibiagio@hsanmartino.it    Principal Investigator: Antonio Di Biagio, M.D.          Divisione di Malattie Infettive, Ospedale San Gerardo Recruiting Monza, MB, Italy Contact: Andrea Gori, M.D.       andrea.gori@unimib.it    Principal Investigator: Andrea Gori, M.D.          Divisione Clinicizzata di Malattie Infettive dell'Università degli Studi, Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" Recruiting Milano, MI, Italy, 20157 Contact: Stefano Rusconi, M.D.       stefano.rusconi@unimi.it    Contact: Elisa Colella, M.D.       elisa_colella@yahoo.it    Principal Investigator: Stefano Rusconi, M.D.          I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario "Luigi Sacco" Recruiting Milano, MI, Italy, 20157 Contact: Giuliano Rizzardini, M.D.       rizzardini.giuliano@hsacco.it    Principal Investigator: Giuliano Rizzardini, M.D.          Clinica Malattie Infettive, Policlinico Universitario Not yet recruiting Modena, MO, Italy Contact: Cristina Mussini, M.D.       crimuss@unimore.it    Principal Investigator: Cristina Mussini, M.D.          U.O. Malattie Infettive, Policlinico S. Matteo Recruiting Pavia, PV, Italy Contact: Renato Maserati, M.D.       rmaserati@smatteo.pv.it    Principal Investigator: Renato Maserati, M.D.          Clinica delle Malattie Infettive, Policlinico "Tor Vergata" Recruiting Roma, RM, Italy Contact: Massimo Andreoni, M.D.       andreoni@uniroma2.it    Contact: Loredana Sarmati, M.D.       sarmati@med.uniroma2.it    Principal Investigator: Massimo Andreoni, M.D.          Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore Not yet recruiting Roma, RM, Italy Contact: Simona Di Giambenedetto, M.D.       simona.digiambenedetto@rm.unicatt.it    Principal Investigator: Simona Di Giambenedetto, M.D.          U.O. Malattie Infettive, Azienda Policlinico Umberto I, Università degli Studi "La Sapienza" Recruiting Roma, RM, Italy Contact: Vincenzo Vullo, M.D.       vincenzo.vullo@uniroma1.it    Contact: Gabriella D'Ettorre, M.D.       gabriella.dettorre@uniroma1.it    Principal Investigator: Vincenzo Vullo, M.D.          Clinica delle Malattie Infettive, Ospedale Amedeo di Savoia, Università degli Studi Recruiting Torino, TO, Italy Contact: Stefano Bonora, M.D.       stefano.bonora@unito.it    Principal Investigator: Stefano Bonora, M.D. Less <<
NCT02120352 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 2 Active, not recruiting December 31, 2020 -
NCT02345226 HIV-1 Infection Phase 3 Active, not recruiting December 2018 -
NCT02345226 - Active, not recruiting - -
NCT03639311 HIV Infections Phase 2 Not yet recruiting November 30, 2020 United States, Florida ... More >> GSK Investigational Site Not yet recruiting Fort Lauderdale, Florida, United States, 33316 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    United States, Texas GSK Investigational Site Not yet recruiting Dallas, Texas, United States, 75246 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com Less <<
NCT02345252 HIV-1 Infection Phase 3 Active, not recruiting December 2018 -
NCT02345252 - Active, not recruiting - -
NCT02707601 - Completed - -
NCT01309243 HIV-1 Infection Phase 3 Completed - -
NCT01309243 - Completed - -
NCT02042001 Impaired Cognition ... More >> Depression/Anxiety Poor Quality Sleep Quality of Life HIV-1 Infection Less << Phase 4 Completed - Italy ... More >> Clinic of Infectious Diseases, AO San Gerardo Monza, MB, Italy, 20900 Spedali Civili - University of Brescia Brescia, Italy Clinica di Malattie Infettive, Ospedale San Martino Genova, Italy AO San Paolo - University of Milan Milan, Italy Ospedale Amedeo di Savoia - University of Turin Torino, Italy Less <<
NCT02478632 HIV Infections Phase 3 Completed - -
NCT02478632 - Completed - -
NCT02707601 HIV-1 Infection ... More >> HCV Infection Less << Phase 3 Completed - -
NCT01205139 Hepatitis C Virus Phase 1 Completed - -
NCT03518060 - Recruiting December 1, 2021 Germany ... More >> GSK Investigational Site Not yet recruiting Tuebingen, Baden-Wuerttemberg, Germany, 72076 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Muenchen, Bayern, Germany, 80331 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Muenchen, Bayern, Germany, 80335 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Muenchen, Bayern, Germany, 80336 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Muenchen, Bayern, Germany, 80801 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Muenchen, Bayern, Germany, 81675 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Osnabrueck, Niedersachsen, Germany, 49090 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Aachen, Nordrhein-Westfalen, Germany, 52062 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Bochum, Nordrhein-Westfalen, Germany, 44787 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Koeln, Nordrhein-Westfalen, Germany, 50674 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Muenster, Nordrhein-Westfalen, Germany, 48143 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Berlin, Germany, 10117 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Berlin, Germany, 10243 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Berlin, Germany, 10707 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Berlin, Germany, 10777 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Berlin, Germany, 12163 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Berlin, Germany, 14057 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Berlin, Germany, 14059 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Chemnitz, Germany, 09111 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Hamburg, Germany, 20099 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Hamburg, Germany, 20146 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Koeln, Germany, 50668 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Weimar, Germany, 99427 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com Less <<
NCT03251690 Anti-Retroviral Agents ... More >> Efavirenz HIV-1-infection Sustained Virologic Response Dyslipidemias Rilpivirine Less << Not Applicable Active, not recruiting March 31, 2018 -
NCT01286740 - Completed - -
NCT01252940 HIV-1 Infection Phase 3 Completed - -
NCT01593046 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 1 Completed - United States, Florida ... More >> GSK Investigational Site Daytona Beach, Florida, United States, 32117 United States, Kansas GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT01777997 HIV-1 Infection Phase 4 Completed - United States, Alabama ... More >> 31788 Alabama CRS Birmingham, Alabama, United States, 35294 United States, California 801 University of California, San Francisco HIV/AIDS CRS San Francisco, California, United States, 94110 United States, District of Columbia Whitman Walker Health CRS (31791) Washington, District of Columbia, United States, 20009 United States, Georgia The Ponce de Leon Ctr. CRS (5802) Atlanta, Georgia, United States, 30308 United States, Illinois Northwestern University CRS (2701) Chicago, Illinois, United States, 60611 Rush Univ. Med. Ctr. ACTG CRS (2702) Chicago, Illinois, United States, 60612 United States, Maryland IHV Baltimore Treatment CRS (4651) Baltimore, Maryland, United States, 21201 United States, Massachusetts Massachusetts General Hospital ACTG CRS (101) Boston, Massachusetts, United States, 02114 Brigham and Women's Hosp. ACTG CRS (107) Boston, Massachusetts, United States, 02115 United States, New York Bronx-Lebanon Hosp. Ctr. CRS (31469) Bronx, New York, United States, 10457 University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) Rochester, New York, United States, 14642 United States, North Carolina Unc Aids Crs (3201) Chapel Hill, North Carolina, United States, 27516 Moses H. Cone Memorial Hospital CRS (3203) Greensboro, North Carolina, United States, 27401 United States, Ohio University of Cincinnati CRS (2401) Cincinnati, Ohio, United States, 45267 Metro Health CRS (2503) Cleveland, Ohio, United States, 44109 United States, Pennsylvania Hosp. of the Univ. of Pennsylvania CRS (6201) Philadelphia, Pennsylvania, United States, 19104 Pitt CRS (1001) Pittsburgh, Pennsylvania, United States, 15213 United States, Rhode Island The Miriam Hosp. ACTG CRS (2951) Providence, Rhode Island, United States, 02906 United States, Texas Houston AIDS Research Team CRS (31473) Houston, Texas, United States, 77030 Less <<
NCT01777997 - Completed - -
NCT01286740 HIV-1 Infection Phase 2 Completed - United States, California ... More >> Living Hope Clinical Foundation Long Beach, California, United States, 90814 Peter J. Ruane MD Inc Los Angeles, California, United States, 90036 Anthony Mills MD, Inc. Los Angeles, California, United States, 90069 La Playa Medical Group and Clinical Research San Diego, California, United States, 92103 United States, District of Columbia Dupont Circle Physicians Group, P.C. Washington, District of Columbia, United States, 20009 Whitman Walker Clinic Washington, District of Columbia, United States, 20009 Capital Medical Associates, PC Washington, District of Columbia, United States, 20036 United States, Florida The Kinder Medical Group Miami, Florida, United States, 33133 Orlando Immunology Center Orlando, Florida, United States, 32803 United States, Georgia Atlanta ID Group Atlanta, Georgia, United States, 30309 Infectious Disease Specialists of Atlanta Decatur, Georgia, United States, 30033 United States, Illinois Northstar Medical Center Chicago, Illinois, United States, 60657 United States, Massachusetts Community Research Initiative of New England Boston, Massachusetts, United States, 02215 United States, Michigan Be Well Medical Center, P.C. Berkley, Michigan, United States, 48072 United States, Missouri Southampton Healthcare, Inc. St. Louis, Missouri, United States, 63139 United States, Texas Southwest Infectious Disease Clinical Research, Inc. Addison, Texas, United States, 75001 Central Texas Clinical Research Austin, Texas, United States, 78705 United States, Washington Peter Shalit, M.D. Seattle, Washington, United States, 98104 Less <<
NCT02429791 HIV Infections Phase 3 Active, not recruiting August 13, 2021 -
NCT01252940 - Completed - -
NCT03299049 HIV Infections Phase 3 Active, not recruiting March 11, 2022 -
NCT02422797 HIV Infections Phase 3 Active, not recruiting August 12, 2021 -
NCT02529059 HIV Phase 4 Completed - United Kingdom ... More >> Brighton & Sussex University Hospitals Nhs Trust Brighton, United Kingdom St. Mary's Hospital London, United Kingdom St. Stephen's Centre London, United Kingdom Less <<
NCT01641809 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 2 Active, not recruiting November 20, 2018 -
NCT02938520 HIV Infections Phase 2 Phase 3 Active, not recruiting July 7, 2022 -
NCT02422797 - Active, not recruiting - -
NCT01796431 HIV Phase 1 Completed - United Kingdom ... More >> St Stephen's AIDS Trust London, United Kingdom, SW10 9NH Less <<
NCT00543725 HIV Infections ... More >> HIV-1 Less << Phase 3 Completed - -
NCT01336829 Hepatitis C H... More >>IV Less << Phase 1 Completed - Belgium ... More >> Antwerp, Belgium Less <<
NCT00543725 - Completed - -
NCT02882230 - Not yet recruiting February 2020 -
NCT02741557 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 1 Completed - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT02429791 - Active, not recruiting - -
NCT02373930 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 1 Completed - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT00110305 Human Immunodeficiency Virus T... More >>ype 1 Less << Phase 2 Completed - -
NCT00110305 - Completed - -
NCT00812292 Pharmacokinetics|Bioavailabili... More >>ty|HIV-1 Less << PHASE1 COMPLETED 2025-04-09 -
NCT00855335 HIV HIV Infec... More >>tions Pregnancy Less << Phase 3 Completed - United States, Florida ... More >> Daytona Beach, Florida, United States Jacksonville, Florida, United States Miami, Florida, United States Pensacola, Florida, United States Port Saint Lucie, Florida, United States West Palm Beach, Florida, United States United States, Georgia Savannah, Georgia, United States United States, Illinois Chicago, Illinois, United States United States, Massachusetts Springfield, Massachusetts, United States United States, Michigan Dearborn, Michigan, United States United States, New York Bronx, New York, United States Syracuse, New York, United States United States, North Carolina Chapel Hill, North Carolina, United States Greensboro, North Carolina, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Texas Bellaire, Texas, United States Puerto Rico San Juan Pr, Puerto Rico Less <<
NCT00741741 HIV-1 PHASE1 TERMINATED 2025-11-09 -
NCT00540449 HIV Infections ... More >> HIV-1 Human Immunodeficiency Virus Type 1 Less << Phase 3 Completed - -
NCT00855335 - Completed - -
NCT00744809 Human Volunteers Phase 1 Completed - -
NCT00744770 HIV PHASE1 COMPLETED 2025-06-09 -
NCT01031589 HIV Infections Phase 1 Completed - -
NCT00739622 HIV|AIDS|Oral Contraceptive PHASE1 COMPLETED 2025-12-08 -
NCT00736905 HIV|AIDS|Hepatic Impairment PHASE1 COMPLETED 2025-11-09 -
NCT00540449 - Completed - -
NCT01709084 Human Immunodeficiency Virus-t... More >>ype 1 Infection Less << Phase 3 Active, not recruiting December 31, 2020 Cameroon ... More >> Douala, Cameroon Yaounde, Cameroon Kenya Eldoret, Kenya Kangemi, Nairobi, Kenya Nairobi, Kenya Nyanza, Kenya Senegal Dakar, Senegal Pikine, Senegal South Africa Bloemfontein, South Africa Johannesburg, South Africa Soweto, South Africa Wentworth, Durban, South Africa Westville, Kwazulu, South Africa Thailand Amphur Mueang Nonthaburi, Thailand Bangkok, Thailand Chiang Mai, Thailand Uganda Entebbe, Uganda Kampala, Uganda Less <<
NCT01715636 HIV Nonoccupational Post-expos... More >>ure Prophylaxis in Men Who Have Sex With Men Less << Phase 4 Completed - Australia, New South Wales ... More >> Sydney Sexual Heatlh Centre Sydney, New South Wales, Australia, 2000 St Vincents Hospital Sydney, New South Wales, Australia, 2010 Australia, Victoria The Alfred Hospital Melbourne, Victoria, Australia, 3004 Melbourne Sexual Health Centre Melbourne, Victoria, Australia, 3053 Less <<
NCT01709084 - Active, not recruiting - -
NCT02069834 HIV Infection ... More >> HAART-treated Virologically Controlled Less << Phase 2 Phase 3 Withdrawn(One of the both Fund... More >>er partners decided to stop the study before the initiation thus no product provided and no funding to realize the study) Less << October 2017 France ... More >> CHU Guadeloupe Point-a-pitre, Guadeloupe, France, 97159 CHU de Fort de France Fort de France, Martinique, France, 87261 Chu Jean Minjoz Besançon, France, 25030 Hôpital Avicenne Bobigny, France, 93000 Hôpital Jean Verdier Bondy, France, 93140 CHU de Bordeaux Bordeaux, France, 33076 CHU de DIJON Dijon, France, 21079 CHD La Roche sur Yon La Roche sur Yon, France, 85925 CHU Kremlin Bicêtre Le Kremlin Bicetre, France, 94275 Hôpital Perpetuel Secours Levallois-perret, France, 92300 CHU de Nantes Nantes, France, 44093 Hôpital Saint Louis Paris Cedex 10, France, 75475 CHU BICHAT - Claude Bernard Paris cedex 18, France, 75877 CHU Hôtel Dieu Paris Paris, France, 75004 Hôpital La Pitié Salpêtrière Paris, France, 75013 Hôpital Necker - enfants Malades Paris, France, 75015 Hôpital Européen Georges Pompidou Paris, France, 75908 CHU de Rennes - Hôpital Pontchaillou Rennes, France, 35000 CH Delafontaine Saint Denis, France, 93200 CHU Saint Etienne Saint Etienne, France, 42055 CHU de Strasbourg Strasbourg, France, 67091 Hôpital FOCH Suresnes, France, 92150 CHU Toulouse Toulouse, France, 31059 CHRU de Tours Tours Cedex 09, France, 37044 CHU de Nancy VANDOEUVRE LES NANCY cedex, France, 54511 Less <<
NCT01467531 Infections, Human Immunodefici... More >>ency Virus and Hepatitis Less << Phase 1 Completed - United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT03589040 HIV Contracep... More >>tion Less << Phase 2 Not yet recruiting June 2020 Uganda ... More >> Infectious Diseases Institue Not yet recruiting Kampala, Uganda, 256 Contact: Stephen Research Manager    0392878652    sokoboi@idi.co.ug    Principal Investigator: Mohammed Lamorde, PhD          Sub-Investigator: Kimberley Scarsi, PharmD,MSc          Sub-Investigator: Catherine Chappell, MD, MSc          Sub-Investigator: Saye Khoo, PhD          Sub-Investigator: Pauline Byakika, PhD          Sub-Investigator: Kristin Darin, PharmD          Sub-Investigator: Shadia Nakalema, MBChB, DTM&H          Sub-Investigator: Stephen Walimbwa, MD          Sub-Investigator: Julian Kaboggoza, BPharm Less <<
NCT03497676 HIV Infections Phase 1 Phase 2 Not yet recruiting August 2023 United States, Colorado ... More >> Univ. of Colorado Denver NICHD CRS Not yet recruiting Aurora, Colorado, United States, 80045 Contact: Emily Barr, C.P.N.P., C.N.M., M.S.N.    720-777-6752    emily.barr@childrenscolorado.org    United States, Maryland Johns Hopkins Univ. Baltimore NICHD CRS Not yet recruiting Baltimore, Maryland, United States, 21287 Contact: Aleisha Collinson-Streng, R.N., A.C.R.N.    443-801-7301    acolli14@jhmi.edu    United States, New York Bronx-Lebanon Hospital Center NICHD CRS Not yet recruiting Bronx, New York, United States, 10457 Contact: Martha Cavallo, A.N.P., C.R.N.P.    718-960-1010    mcavallo@bronxleb.org    Jacobi Med. Ctr. Bronx NICHD CRS Not yet recruiting Bronx, New York, United States, 10461 Contact: Marlene Burey, R.N., M.S.N., P.N.P.    718-918-4783    marlene.burey@nychhc.org    United States, Tennessee St. Jude Children's Research Hospital CRS Not yet recruiting Memphis, Tennessee, United States, 38105-3678 Contact: Patricia M. Flynn, M.D.    901-595-2338    pat.flynn@stjude.org    United States, Washington Seattle Children's Research Institute CRS Not yet recruiting Seattle, Washington, United States, 98101 Contact: Amanda Robson Nuss, B.S.    206-884-1535    amanda.robson@seattlechildrens.org    Puerto Rico San Juan City Hosp. PR NICHD CRS Not yet recruiting San Juan, Puerto Rico, 00936 Contact: Lizbeth Fabregas-Troche, B.S., M.S.    787-764-3083    lfabregas@sanjuanciudadpatria.com Less <<
NCT01975012 HIV Infections PHASE1|PHASE2 WITHDRAWN - -
NCT01275443 HIV Infection Phase 1 Completed - United Kingdom ... More >> St Stephen's AIDS Trust London, United Kingdom, SW10 9NH Less <<
NCT02951052 Infection, Human Immunodeficie... More >>ncy Virus Less << Phase 3 Active, not recruiting February 8, 2022 -
NCT01049932 HIV Infections Phase 1 Phase 2 Terminated(Trial closed due to... More >> additional safety information.) Less << - United Kingdom ... More >> Royal Sussex County Hospital Brighton, Sussex, United Kingdom, BN2 5BE St. Thomas's Hospital London, United Kingdom, SE1 7EH St Stephen's Centre London, United Kingdom, SW10 9TH St. Mary's Hospital London, United Kingdom, W2 1NY Less <<
NCT01001247 HIV Infections Phase 1 Completed - -
NCT01266902 HIV-1 Infection PHASE3 COMPLETED 2025-02-20 Beverly Hills, California, Uni... More >>ted States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Sacramento, California, United States|Washington, District of Columbia, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Minneapolis, Minnesota, United States|Albany, New York, United States|Bronx, New York, United States|New York, New York, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Cordoba, Argentina|Guernica, Argentina|Rosario, Argentina|Darlinghurst, Australia|Melbourne, Australia|Perth, Australia|Surry Hills, Australia|Victoria, Australia|Vienna, Austria|Wien, Austria|Antwerpen, Belgium|Brussels, Belgium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal N/a, Canada|Santiago, Chile|Beijing, China|Guangzhou, China|Shanghai, China|Copenhagen, Denmark|Hvidovre N/a, Denmark|Odense N/a, Denmark|Clamart, France|Lyon, France|Nantes, France|Paris Cedex 10, France|Paris Cedex 12, France|Paris Cedex 18, France|Paris, France|Tourcoing, France|Berlin, Germany|Essen, Germany|Frankfurt, Germany|Hamburg, Germany|Hannover, Germany|K?ln, Germany|Rotterdam, Netherlands|San Juan, Puerto Rico|Bucuresti, Romania|Iasi, Romania|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow N/a, Russian Federation|Saint-Petersburg, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Volgograd, Russian Federation|Voronezh, Russian Federation|Bloemfontein, South Africa|Dundee, South Africa|Durban, South Africa|Johannesburg Gauteng, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Westdene Johannesburg Gauteng, South Africa|Alicante, Spain|Barcelona, Spain|Elche, Spain|Madrid, Spain|Stockholm, Sweden|Kaohsiung County, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Brighton, United Kingdom|London, United Kingdom|Manchester, United Kingdom Less <<
NCT01519128 Healthy Phase 1 Completed - Belgium ... More >> Merksem, Belgium Less <<
NCT00799864 Human Immuno Deficiency (HIV) ... More >>Infection Less << Phase 2 Recruiting August 20, 2027 United States, New York ... More >> SUNY Upstate Medical University Recruiting Syracuse, New York, United States, 13210 United States, Tennessee St Jude Children's Research Hospital Completed Memphis, Tennessee, United States, 38105 United States, Virginia Children'S Hospital of the King'S Daughters Withdrawn Norfolk, Virginia, United States, 23507 India Yr Gaitonde Center For Aids Research and Education Completed Chennai, India, 600113 Kasturba Medical College Hospital Completed Mangalore, India, 575001 Kenya Kenya Medical Research Institute/Walter Reed Project Not yet recruiting Kericho, Kenya, 20200 KAVI Institute of Clinical Research Recruiting Nairobi, Kenya, 254 Romania Spitalul de Boli Infectioase si Tropicale 'Dr. Victor Babes' Completed Bucuresti, Romania, 030317 South Africa Boanerges Clinical Research Completed Bloemfontein, South Africa, 9301 Josha Research Recruiting Bloemfontein, South Africa, 9301 Jan Fourie Medical Practice Completed Dundee, South Africa, 3000 University of KwaZulu-Natal Withdrawn Durban, South Africa, 4001 Harriet Shezi Childrens Clinic, Paediatric Department Withdrawn Johannesburg Gauteng, South Africa, 2013 Mzansi Ethical Research Centre Recruiting Middelburg, South Africa, 1055 Triple M Research Withdrawn Port Elizabeth, South Africa, 6070 Synexuss Sastanza Completed Pretoria, South Africa, 0122 Limpopo Clinical Research Initiative Recruiting Thabazimbi, South Africa, 380 East Rand Urology Research Unit Not yet recruiting Vosloorus, South Africa, 1475 Thailand Thai Red Cross Aids Research Centre Completed Bangkok, Thailand, 10330 Queen Sirikit National Institute of Child Health Withdrawn Bangkok, Thailand, 10400 Bamrasnaradura Infectious Disease Institute Recruiting Nonthaburi, Thailand, 11000 Uganda Mrc/ Uvri Uganda Research Unit on Aids Not yet recruiting Entebbe, Uganda Joint Clinical Research Centre Recruiting Kampala, Uganda, 10005 Makerere University Medical School Withdrawn Kampala, Uganda Ukraine Center Clinic for treatment HIV positive children Completed Kiev, Ukraine, 01135 Less <<
NCT01804244 Healthy PHASE4 COMPLETED 2025-03-13 Tokyo, Japan
NCT01268839 HIV Phase 1 Completed - -
NCT03127189 Healthy Phase 1 Completed - United States, Arizona ... More >> Celerion Tempe, Arizona, United States, 85283 United States, Nebraska Celerion Lincoln, Nebraska, United States, 68502 Less <<
NCT01736761 HIV Phase 4 Completed - United Kingdom ... More >> St Stephen's AIDS Trust London, United Kingdom, SW10 9TH Less <<
NCT01701882 HIV Phase 3 Completed - United Kingdom ... More >> St Stephen's AIDS Trust London, United Kingdom, SW10 9TH Less <<
NCT01585038 Cardiovascular Disease Phase 4 Completed - United States, Indiana ... More >> Indiana Clinical and Translational Sciences Institute Indianapolis, Indiana, United States, 46202 Less <<
NCT01585038 - Completed - -
NCT01656018 Healthy Phase 1 Completed - United States, Pennsylvania ... More >> Pittsburgh, Pennsylvania, United States Less <<
NCT03567304 HIV-1-infection ... More >> Neurocognitive Dysfunction Less << Phase 4 Recruiting July 2020 Thailand ... More >> Chiang Mai University Hospital Recruiting Chiang Mai, Thailand, 50200 Contact: Quanhathai Kaewpoowat, MD    6653936148    quanhathai@rihes.org    Contact: Wirongrong Thongton, MD    6653936148    wirongrong1983@gmail.com Less <<
NCT02104700 HIV Phase 2 Phase 3 Unknown July 2016 Rwanda ... More >> Rwanda Military Hospital Kinombe, Rwanda Less <<
NCT01692470 - Withdrawn(The company decided ... More >>to cancel this study in conformity with Philippines FDA Circular 2013-004) Less << December 2015 -
NCT02165202 Human Immunodeficiency Virus (... More >>HIV) Less << Phase 2 Completed - United States, New Jersey ... More >> New Jersey Medical School Clinical Research Center Newark, New Jersey, United States, 07103 United States, New York Bronx Prevention Center Bronx, New York, United States, 10451 South Africa Emavundleni Clinical Research Site Cape Town, South Africa Zimbabwe Spilhaus Clinical Research Site Belgravia, Harare, Zimbabwe Less <<
NCT01288755 HIV Infections Phase 1 Completed - -
NCT01719614 Healthy Participants Phase 1 Completed - United States, Kansas ... More >> Overland Park, Kansas, United States Less <<
NCT03664440 Efficacy of Rilpivirine-based ... More >>Regimens as Switch Therapy Less << Not Applicable Completed - Thailand ... More >> Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok, Thailand Less <<
NCT02561936 Healthy Phase 1 Completed - Belgium ... More >> Antwerp, Belgium Less <<
NCT02404233 HIV Positive Phase 4 Unknown December 2016 United States, Texas ... More >> Therapeutic Concepts, P.A. Not yet recruiting Houston, Texas, United States, 77004 Contact: Joseph C. Gathe, M.D.    713-526-9821    drgathe@josephgathe.com    Contact: Valerie H. Davis, B.S.    713-526-9821    vdavis@josephgathe.com    Principal Investigator: Joseph C. Gathe, M.D.          Therapeutic Concepts, PA Houston, Texas, United States, 77004 Less <<
NCT01615614 Healthy Phase 1 Completed - Belgium ... More >> Merksem, Belgium Less <<
NCT02547870 Human Immunodeficiency Virus T... More >>ype 1 Less << Phase 1 Completed - Belgium ... More >> Antwerp, Belgium Less <<
NCT02165202 - Completed - -
NCT03589027 HIV-1-infection ... More >> Contraception Less << Phase 2 Recruiting June 2020 Uganda ... More >> Infectious Diseases Institue Recruiting Kampala, Uganda, 256 Contact: Stephen Research Manager    0392878652    sokoboi@idi.co.ug    Principal Investigator: Mohammed Lamorde, PhD          Sub-Investigator: Kimberley Scarsi, PharmD,MSc          Sub-Investigator: Catherine Chappell, MD, MSc          Sub-Investigator: Saye Khoo, PhD          Sub-Investigator: Pauline Byakika, PhD          Sub-Investigator: Kristin Darin, PharmD          Sub-Investigator: Shadia Nakalema, MBChB, DTM&H          Sub-Investigator: Stephen Walimbwa, MD          Sub-Investigator: Julian Kaboggoza, BPharm Less <<
NCT02530060 Healthy Phase 4 Completed - Japan ... More >> Fukuoka, Japan Less <<
NCT01562886 HIV PHASE1 COMPLETED 2025-02-13 Imperial College Healthcare NH... More >>S Trust, London, W2 1NY, United Kingdom Less <<
NCT03033368 HIV PHASE2|PHASE3 UNKNOWN 2025-12-17 -
NCT01562886 HIV PHASE1 COMPLETED 2025-02-13 Imperial College Healthcare NH... More >>S Trust, London, W2 1NY, United Kingdom Less <<
NCT02494986 Human Immunodeficiency Virus T... More >>ype 1 Less << PHASE2 ACTIVE_NOT_RECRUITING 2031-12-31 Porto, Portugal|Bloemfontein, ... More >>South Africa|Dundee, South Africa|Esplugues De Llobregat, Spain|Bangkok, Thailand|Nonthaburi, Thailand|Entebbe, Uganda|Kampala, Uganda Less <<
NCT03563742 Human Immunodeficiency Virus I... More >>nfections Less << Phase 3 Recruiting August 31, 2020 India ... More >> St.Johns Medical College and Hospital Not yet recruiting Bengaluru, India, 560034 YRGCARE Not yet recruiting Chennai, India, 600113 Manipal University-Kasturba Medical College Recruiting Mangalore, India, 575001 Lata Mangeshkar Hospital Recruiting Nagpur, India, 440001 Deenanath Mangeshkar Hospital and Research Centre Recruiting Pune, India, 411004 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.73mL

0.55mL

0.27mL

13.65mL

2.73mL

1.36mL

27.29mL

5.46mL

2.73mL

References

 

Historical Records

Categories